menu
    • menu
    [{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Fampridine","moa":"Voltage-gated Potassium Channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Prolonged Release","sponsorNew":"Acorda Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Biogen"}]

    Find Clinical Drug Pipeline Developments & Deals for Dalfampridine

    Menu

    Dalfampridine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Acorda Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Acorda Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fampridine

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Biogen

    Deal Size : $510.0 million

    Deal Type : Termination

    DEALS_DEV arrow-down

    Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

    Details : Following termination, Acorda regains global commercialization rights to Fampyra, a prolonged-release formulation of fampridine (4-aminopyridine) for adults with multiple sclerosis.

    Product Name : Fampyra

    Product Type : Other Small Molecule

    Upfront Cash : $110.0 million

    November 01, 2024

    Lead Product(s) : Fampridine

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Biogen

    Deal Size : $510.0 million

    Deal Type : Termination

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth